GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

GLP-1: Glucagon-like peptide-1 ... Published and preliminary data have shown once-weekly exenatide to result in greater A1c reduction than exenatide twice daily; and as a second- or third-line ...

The once- and twice-daily GLP-1 RAs are now well established for ... has been shown in most studies to result in a greater reduction of A1c and FPG. While it has not been compared head-to-head ...

As Ozempic and other GLP-1 drugs explode in popularity ... the allure of a "miracle" weight loss solution – an average 15% weight reduction, according to clinical research – that reduces ...

while the relative reduction with GLP-1 receptor agonist use was less in older versus younger participants. Sex was not associated with differences in efficacy for any of the diabetes treatments ...

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.